在乳腺癌分子亚型中比较无病生存率
Maryam Esmati1, Fatemeh Monfaredi1, Mohsen Vakili Sadeghi2
1Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Caspian journal of internal medicine
|December 2, 2024
概括
三重阴性乳腺癌和Her-2丰富亚型显示较短的无病生存期 (DFS). 瘤阶段也是影响乳腺癌患者复发的关键因素.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 临床研究 临床研究
背景情况:
- 乳腺癌的治疗以分子亚型为指导.
- 了解亚型之间的生存差异对于治疗策略至关重要.
研究的目的:
- 在不同乳腺癌分子亚型中比较无病生存期 (DFS).
- 为了确定复发的独立预后因素.
主要方法:
- 在2009年至2015年期间对221名乳腺癌患者进行治疗的横截面研究.
- 使用圣盖伦标准确定的分子亚型:光线A,光线B (HER2+,HER2-),HER2丰富,三阴性.
- 考克斯回归分析用于比较DFS和整体生存期 (OS).
主要成果:
- 光线B,HER2-阴性是最常见的亚型 (35.5%).
- 五年无进展生存率 (PFS) 范围从76% (HER2丰富) 到95.5% (Luminal B,HER2阳性).
- 瘤阶段 (HR=5.9) 和三阴性亚型 (HR=5.2) 是复发的独立预测因素.
结论:
- 与光子亚型相比,三阴性和潜在的HER-2丰富乳腺癌的DFS较短.
- 晚期瘤阶段是乳腺癌复发的重要独立因素.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
150
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
150
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328


